This site provides research and comparisons, not medical advice. Consult your pediatrician before changing your baby's formula.
FDA enforcement discretion is a regulatory framework where the Food and Drug Administration chooses not to enforce against specific activities that would technically be subject to FDA authority. For infant formula specifically, the enforcement discretion permits personally imported European and other non-FDA-registered formulas for family use — even though those formulas aren't FDA-registered for direct US retail.
What FDA enforcement discretion is and isn't
What it is: A regulatory pathway where FDA explicitly states it will not enforce certain rules against certain activities. For infant formula imports, the discretion covers personally imported formulas for family use — typically up to a 90-day supply per import event. The framework was formally expanded during the 2022 formula shortage to address the supply crisis and remains in place.
What it isn't: FDA enforcement discretion is NOT FDA approval, FDA registration, or any positive endorsement of the formula's quality, safety, or compliance. The formula remains non-FDA-registered for direct US retail purposes. The discretion simply means FDA chooses not to enforce against personal-use imports — typically because the alternative (forcing families to abandon their preferred formulas) creates worse outcomes than allowing the personal-use pathway.
Practical implication: Importing HiPP, Holle, Loulouka, Lebenswert, or similar EU formulas through reseller services (Organic's Best Shop, Formuland, MyOrganicFormula) for family use is legal under enforcement discretion. Commercial distribution of those same formulas through US retail (Target, Walmart, Amazon direct) without FDA registration would be a different regulatory question and is not what enforcement discretion covers.
Why FDA enforcement discretion exists for infant formula imports
The regulatory framework before enforcement discretion treated unregistered infant formula imports as technical violations of FDA rules — even for personal family use. This created practical problems:
Pre-2022 context. Many European formulas (HiPP, Holle, Aptamil) have been preferred by families for decades due to compositional differences (lactose-only carbohydrate mandate, EU Organic certification, probiotic strain inclusion). The pre-2022 framework left these families in regulatory ambiguity — the imports were technically violations but typically not enforced against.
2022 formula shortage. The Abbott Sturgis Cronobacter recall in February 2022 plus the subsequent supply crisis created acute shortages of FDA-registered formulas. Many families could not find their preferred formulas at retail. FDA expanded enforcement discretion to allow broader importation of unregistered formulas to fill the gap.
Post-shortage continuation. The shortage acute phase resolved by mid-2023, but FDA enforcement discretion for personally imported infant formulas remained in place. The framework has now been codified for several years and reseller operations (Organic's Best, Formuland, etc.) operate within it.
What enforcement discretion covers in practice
The discretion permits:
- Personal-use imports of unregistered formulas. Up to typical 90-day family supply per import event from established manufacturers.
- Reseller-mediated imports. Resellers operating US-warehouse distribution receive bulk imports from European manufacturers, authenticate batches, and fulfill personal-use orders to US families.
- DDP shipping pathways. Customs duties pre-paid by the reseller, eliminating surprise import fees for families.
The discretion does NOT cover:
- Direct US retail of unregistered formulas. HiPP, Holle, etc. cannot be sold on US retail shelves (Target, Walmart) without FDA registration.
- Commercial-scale importation for retail distribution. Not covered by personal-use enforcement discretion.
- Hospital or medical-care use of unregistered formulas. Hospitals and pediatric practices typically must use FDA-registered formulas for clinical care.
How this differs from FDA-registered formulas
FDA-registered formulas (Bobbie, Earth's Best, Similac, Enfamil, Kendamil US) have completed the FDA pre-market notification process required by FDA 21 CFR Part 107 for direct US distribution. The notification process verifies nutritional adequacy, manufacturing facility compliance with FDA quality standards, and labeling compliance. FDA-registered formulas are subject to FDA recall authority, FDA inspection, and direct FDA enforcement.
FDA enforcement discretion formulas have not completed this US registration process — they comply with their origin country's regulatory framework instead (EU 2016/127 for European formulas, FSANZ for Australian/New Zealand formulas, etc.). For personal-use imports under enforcement discretion, the family relies on the origin country's regulatory framework rather than FDA registration specifically.
The clinical-outcome implications are subtle. EU 2016/127 and FDA 21 CFR 107 are both robust nutritional adequacy frameworks, with some compositional differences (EU mandates lactose predominance in Stage 1; FDA permits maltodextrin or corn syrup solids; EU mandates higher DHA levels; etc.). Both frameworks produce safe, nutritionally adequate Stage 1 formulas — neither is unsafe by clinical-outcome measures.
Sources
FDA enforcement discretion guidance for personally imported infant formula, US Customs and Border Protection personal-use guidance, and FDA 21 CFR Part 107 provide the regulatory framework governing personally imported infant formulas for families.